Axitinib injectable suspension (Clearside Biomedical)

阿西替尼混悬液 (Clearside Biomedical)

Report date: 2023/12/27 16:07:36

Base Information

Drug NameAxitinib injectable suspension (Clearside Biomedical)
Drug Alias NameAxitinib injectable suspension阿西替尼眼科用药 (Clearside Biomedical)Axitinib ophthalmicCLS-1002CLS-011-A +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor beta inhibitorsVascular endothelial growth factor receptor 1 antagonistsVascular endothelial growth factor receptor 2 antagonists +[4] 
TargetsPlatelet-derived growth factor receptor betaVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 2 +[4] 
Therapy Area/IndicationsMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesClearside Biomedical Inc
China Registration ClassN/A

Develop Information

Active CompaniesClearside Biomedical Inc
Inactive CompaniesN/A
Active IndicationsMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A